X
Pfizer might buy BMS for $130bn – but should it?
https://pharmaphorum.com/news/pfizer-might-buy-bms-for-130bn-but-should-it/
BMS
BMS strikes back with lung cancer combo success
Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
Clovis and BMS combine cancer drugs in late-stage trials
Clovis and BMS research small molecule and antibody combination.
The cancer challenge: the quest for a cure is only half the battle
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
AA Gill takes swipe at NICE in final column
NHS initially denied late writer immunotherapy.
Cancer market commentary: Roche’s Tecentriq muscles into NSCLC
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
1 2
